NYSE:ABTAbbott Laboratories Stock Price, Forecast & News

$86.04

+1.09 (+1.28 %)

(As of 04/10/2020 02:10 PM ET)

Add

Compare

Today's Range

$82.95

Now: $86.04▼

$86.50

50-Day Range

$62.82

MA: $79.02▼

$89.36

52-Week Range

$61.61

Now: $86.04▼

$92.45

Volume10.47 million shs

Average Volume14.73 million shs

Market Capitalization$151.73 billion

P/E Ratio41.77

Dividend Yield1.70%

Beta0.93

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Abbott Laboratories has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 13 buy ratings, 5 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $93.33, Abbott Laboratories has a potential upside of 8.5% from its current price of $86.04.
Amount of Analyst Coverage
Abbott Laboratories has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Abbott Laboratories has received 801 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Abbott Laboratories has received 673 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Abbott Laboratories has received 54.34% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote “Outperform” if you believe ABT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.

5.0 Dividend Strength

Dividend Leadership
Abbott Laboratories is a leading dividend payer. It pays a dividend yield of 1.70%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Abbott Laboratories has been increasing its dividend for 47 years.
Dividend Coverage
The dividend payout ratio of Abbott Laboratories is 44.44 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 39.34 % next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,878,762.00 in company stock.
Percentage Held by Insiders
Only 1.70% of the stock of Abbott Laboratories is held by insiders.
Percentage Held by Institutions
75.02% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Abbott Laboratories are expected to grow by 18.45% in the coming year, from $3.09 to $3.66 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Abbott Laboratories is 41.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.47.
Price to Earnings Ratio vs. Sector
The P/E ratio of Abbott Laboratories is 41.77, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.25.
Price to Earnings Growth Ratio
Abbott Laboratories has a PEG Ratio of 2.99. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Abbott Laboratories has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.33 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNYSE:ABT

Previous Symbol

CUSIP00282410

CIK1800

Webhttp://www.abbott.com/

Phone224-667-6100

Debt

Debt-to-Equity Ratio0.53

Current Ratio1.44

Quick Ratio1.04

Price-To-Earnings

Trailing P/E Ratio41.77

Forward P/E Ratio27.84

P/E Growth2.99

Sales & Book Value

Annual Sales$31.90 billion

Price / Sales4.76

Cash Flow$5.06 per share

Price / Cash Flow17.02

Book Value$17.70 per share

Price / Book4.86

Profitability

EPS (Most Recent Fiscal Year)$3.24

Net Income$3.69 billion

Net Margins11.56%

Return on Equity18.39%

Return on Assets8.53%

Miscellaneous

Employees107,000

Outstanding Shares1,763,430,000

Market Cap$151.73 billion

Next Earnings Date4/16/2020 (Confirmed)

OptionableOptionable

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

How has Abbott Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABT stock has increased by 10.2% and is now trading at $86.04. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Abbott Laboratories?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Abbott Laboratories.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, April 16th 2020. View our earnings forecast for Abbott Laboratories.

How can I listen to Abbott Laboratories' earnings call?

Abbott Laboratories will be holding an earnings conference call on Thursday, April 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) issued its earnings results on Wednesday, January, 22nd. The healthcare product maker reported $0.95 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.95. The healthcare product maker earned $8.31 billion during the quarter, compared to the consensus estimate of $8.26 billion. Abbott Laboratories had a return on equity of 18.39% and a net margin of 11.56%. The firm's quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.81 earnings per share. View Abbott Laboratories' earnings history.

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, February 21st. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.36 per share on Friday, May 15th. This represents a $1.44 annualized dividend and a yield of 1.67%. The ex-dividend date of this dividend is Tuesday, April 14th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.08. View Abbott Laboratories' dividend history.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY20 earnings guidance on Wednesday, January, 22nd. The company provided EPS guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.60.

What price target have analysts set for ABT?

19 equities research analysts have issued 1-year price targets for Abbott Laboratories' shares. Their forecasts range from $81.00 to $105.00. On average, they anticipate Abbott Laboratories' stock price to reach $93.33 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price. View analysts' price targets for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

News headlines about ABT stock have trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Abbott Laboratories earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news articles about the healthcare product maker a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAbbott Laboratories.

Are investors shorting Abbott Laboratories?

Abbott Laboratories saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 23,053,500 shares, an increase of 21.5% from the February 27th total of 18,970,000 shares. Based on an average trading volume of 5,550,000 shares, the days-to-cover ratio is presently 4.2 days. Approximately 1.3% of the shares of the company are sold short. View Abbott Laboratories' Current Options Chain.

Who are some of Abbott Laboratories' key competitors?

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD), Varian Medical Systems (VAR) and Hologic (HOLX).

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Walt Disney (DIS), NVIDIA (NVDA), Home Depot (HD), Pfizer (PFE), Verizon Communications (VZ) and Intel (INTC).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the following people:

Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
Mr. Robert B. Ford, Pres & COO (Age 45)
Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional investors include Hexavest Inc. (0.04%), Park National Corp OH (0.03%), State of Alaska Department of Revenue (0.02%), Clifford Swan Investment Counsel LLC (0.02%), Stock Yards Bank & Trust Co. (0.01%) and Abner Herrman & Brock LLC (0.01%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Philip P Boudreau, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View institutional ownership trends for Abbott Laboratories.

Which major investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Hexavest Inc., Centre Asset Management LLC, Dalton Greiner Hartman Maher & Co., Abner Herrman & Brock LLC, Park National Corp OH, Global Trust Asset Management LLC, and Verity & Verity LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Philip P Boudreau, Randel William Woodgrift, Sally E Blount, and Stephen R Fussell. View insider buying and selling activity for Abbott Laboratories.

Which major investors are buying Abbott Laboratories stock?

ABT stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, IBM Retirement Fund, Cullinan Associates Inc., Atlantic Union Bankshares Corp, Gradient Investments LLC, Investment House LLC, Tsfg LLC, and Fulton Bank N.A.. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift. View insider buying and selling activity for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $86.04.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $151.73 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe. View additional information about Abbott Laboratories.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is http://www.abbott.com/.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Featured Article: Book Value Of Equity Per Share – BVPS Explained